<DOC>
	<DOCNO>NCT00413699</DOCNO>
	<brief_summary>The purpose study determine long-term effectiveness safety CP-690,550 treatment rheumatoid arthritis . Subjects eligible study participate another `` qualifying '' study CP-690,550 A sub-study conduct within A3921024 study , study evaluate immune response pneumococcal influenza vaccine patient receive CP-690,550</brief_summary>
	<brief_title>Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects participate randomized `` qualify '' study CP690,550 treatment rheumatoid arthritis Vaccine substudy visit Subjects actively participate Study A3921024 must complete least 3 month continuous 10 mg BID CP690,550 treatment A3921024 define &gt; 80 % compliance prescribe dose consumption CP690,550 previous 3 month . Serious medical condition would make treatment CP690,550 potentially unsafe Vaccine substudy visit 1 . Any documented influenza pneumococcal infection within last 3 month prior randomization study 2 . Received vaccine within 1 month prior randomization study 3 . Received influenza vaccine within 6 month pneumococcal vaccine within 5 year randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>long-term</keyword>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
</DOC>